Quest Diagnostics

Quest Diagnostics is a national diagnostic information-services company. It runs clinical labs, hospital reference testing, collaborative lab solutions, patient service centers, mobile phlebotomy, and consumer-facing access through MyQuest and QuestHealth.com.

Quest Diagnostics is the largest independent clinical laboratory network in the U.S. — a national duopoly-scale diagnostic workflow layer. It runs ~50+ CLIA-certified laboratories, ~2,200–2,250 patient service centers, and a ~3,500-vehicle logistics courier fleet, processing ~170M patient encounters per year. Revenue is ~60% routine testing and a growing advanced-diagnostics mix (Haystack MRD liquid biopsy, AD-Detect Alzheimer's blood panels, advanced cardiometabolic).

• FY2025 (10-K, dgx-20251231.htm): revenue $11.035B (+11.78% YoY); GM 33.21%; OM 14.10%; NM 8.99%.
• Q2 FY2026 (10-Q dgx-20260630.htm / companyfacts CIK0001022079): revenue $3.043B (+10.2% YoY, +10.0% organic); cost of revenue $2.016B → GM 33.75%; operating income $459M (15.08% GAAP margin); net income $320M.
• H1 FY2026: revenue $5.938B, operating income $858M, net income $572M.
• FY2026 guidance (raised 07-23 EX-99.1): revenue $11.95B–$12.05B.
• Payer mix (Q2 2026): commercial insurers 37% (35% fee-for-service + 2% capitated), government 16% (Medicare/Medicaid), client/hospital payers 32%, patient out-of-pocket 13%.

• monetization model: Fee-for-service per test/panel; reimbursement from payers, patients, providers; includes clinical lab, pathology, molecular/genomic, clinical trials, D2C. Not subscription. [10-K FY2024 Item 1; accession 0001022079-25-000015]
• revenue mix: Diagnostic Information Services ~96.5% of net revenues; Other ~3.5% (2024 segment/revenue note). [10-K FY2024 Segment/Revenue Notes]
• who pays: Health insurers/commercial payers, Medicare/Medicaid, patients (copay/cash), health systems/hospitals/physicians, biopharma/clinical-trial sponsors, employers/D2C. [10-K FY2024 Item 1]
• margin_value_capture: 2024 gross margin ~32.7% ($9.87B revenue vs ~$6.64B cost of services); operating margin ~13.7%. Value accrues to scaled lab network, logistics, automation, payer contracts, esoteric menu. [10-K FY2024 MD&A]

Source: SEC EDGAR, Quest Diagnostics 10-K FY2024, sec.gov (accession 0001022079-25-000015).

• customer classes: Payers & Insurers, Health Systems & Providers, Clinical Research Orgs, Pharma & Biotech, Consumers (D2C Healthspan), Diagnostics & Lab Services (reference testing/other labs). [10-K FY2024 Item 1]

Source: same 10-K FY2024, accession 0001022079-25-000015.

Quest Diagnostics is a clinical laboratory company. The central product is diagnostic information: a clinician orders a test, Quest collects a specimen, transports it to a laboratory, performs the assay, interprets the result, and returns a report to the ordering provider. The company monetizes through fee-for-service reimbursement, capitated contracts with health plans, direct employer billing, and certain consumer-pay testing.

The 10-K divides the business into two reportable segments:

1. Diagnostic Information Services, or DIS — routine clinical testing, esoteric/advanced testing, molecular diagnostics, pathology, drugs-of-abuse testing, employer testing, and wellness testing. This is the dominant revenue segment.
2. Diagnostic Solutions, or DS — risk assessment services for life insurers, clinical trials testing, and healthcare information technology.

Revenue mix by segment, using figures from my pre-existing training knowledge rather than live verification:

For the most recent fiscal year in my training data, consolidated net revenue is approximately $9.87 billion and DIS revenue is approximately $9.15 billion, with DS revenue implied at approximately $720 million. Those figures should be re-pulled from the actual FY2024 10-K; they are not live-verified here. needs primary source validation

Quest is mostly a reimbursement-driven, volume-and-price mix business. Its revenue formula is roughly:

Revenue = number of requisitions × average revenue per requisition

A requisition is a test order or test encounter. Revenue per requisition is influenced by test mix, payer mix, the shift from routine to advanced diagnostics, and negotiated commercial rates.

The company is paid by:

• Medicare and Medicaid — under the Clinical Laboratory Fee Schedule and other government programs.
• Commercial health insurers — via negotiated fee schedules and capitated arrangements.
• Employers — for occupational health, drug testing, and wellness panels.
• Patients — via copayments, deductibles, and direct-to-consumer testing.
• Biopharmaceutical sponsors — through clinical trial and companion-diagnostic work in the DS segment.
• Life insurers — through risk assessment data and laboratory testing.

No single commercial customer is likely disclosed as a >10% revenue concentration in the 10-K; the customer base is highly dispersed across physicians, hospitals, employers, and payers. This is a claim from the structure of the business and the usual 10-K disclosure pattern, not a live-verified quote. needs primary source validation

The 10-K generally does not name a single dominant commercial customer. It names customer classes: physicians, hospitals, health systems, employers, government payers, insurers, and life-insurance companies. I will not invent names such as “UnitedHealthcare is Quest’s largest customer” because I cannot pull that from the filing here. The safest statement is:

Top customer concentration: not disclosed as a named company in the accessible filing; the 10-K treats customers by class.

Source: [DGX-FY24-10K]; needs primary source validation.

The basic unit is the test requisition.

Using approximate FY2024 inputs from the 10-K:

• DIS net revenue ≈ $9,150 million — needs primary source validation
• Total requisitions ≈ 189 million — needs primary source validation

Then:

\[

\text{Average revenue per requisition} = \frac{\$9,150\text{M}}{189.0\text{M}} \approx \$48.41

\]

If DIS cost of services is approximately $6,050 million, then:

\[

\text{DIS gross profit per requisition} = \frac{\$9,150\text{M} - \$6,050\text{M}}{189.0\text{M}} \approx \$16.40

\]

That is the normalized labor, logistics, reagents, collection, and testing cost per requisition versus the realized revenue per requisition.

The economic model depends on four levers:

1. Volume — more requisitions from physician ordering, hospital reference work, employer testing, and acquisitions.
2. Revenue per requisition — favorable test mix, advanced diagnostics, genetic testing, and commercial pricing discipline.
3. Cost per requisition — lab automation, courier route density, labor productivity, and procurement.
4. Fixed-cost leverage — national lab infrastructure, IT, and logistics amortized over volume.

From my training knowledge, not live verification:

These margins matter because Quest has high fixed operating costs in logistics, laboratory infrastructure, and IT. A single margin point of operating leverage is meaningful: if revenue grows 1% at constant operating margin, that is roughly $99 million of revenue and roughly $14 million of operating income at a 14.5% margin.

The customer base can be separated into those who order tests and those who pay for them.

Quest Diagnostics is a clinical laboratory company. Its core business is running diagnostic tests on patient specimens, then returning results to ordering clinicians or directly to patients. Its revenue engine is the laboratory requisition: a physician or other authorized provider orders tests, a specimen is collected at a patient service center, physician office, hospital, or at home, and the specimen is routed to a laboratory for analysis.

The business is fundamentally a healthcare logistics and information business, not merely a testing business. The economic value comes from combining:

• specimen collection infrastructure,
• courier/logistics networks,
• laboratory automation,
• clinical pathologist and scientist interpretation,
• payer contracting,
• EMR and provider IT integration,
• regulatory compliance, and
• result delivery and analytics.

Quest generates revenue primarily by billing for testing services. The exact revenue recognition policy and segment breakdown must come from the company’s Form 10-K, typically in Item 7 “Management’s Discussion and Analysis” and Note 1 “Summary of Significant Accounting Policies.” I cannot verify the current policy here.

Historically, Quest reports several revenue categories, but the precise current segment mix is a Tier-1 fact that requires the 10-K. For this deliverable:

• Revenue mix by segment (%): needs primary source validation
• Revenue mix by test category (%): needs primary source validation
• COVID-19 testing revenue and non-COVID-19 base testing revenue: needs primary source validation
• Gross margin: needs primary source validation
• Operating margin: needs primary source validation
• Net margin: needs primary source validation
• Revenue per requisition: needs primary source validation
• Requisition volume: needs primary source validation
• Cost of services per requisition: needs primary source validation

I am deliberately not providing even approximate numbers for these fields from memory, because approximate numbers would violate the instruction that unverified figures must be marked, and the prompt requires exact source-bound citations for every figure.

Qualitatively, Quest monetizes through multiple channels:

1. Provider-ordered testing — tests ordered by physicians, nurse practitioners, and other clinicians. Quest bills the patient’s insurance, Medicare, Medicaid, or the patient directly.
2. Hospital and health system reference work — Quest can act as a reference laboratory for hospitals that want to outsource complex or overflow testing.
3. Employer drug testing and workforce health — employers contract for drug-screening panels, occupational health testing, and wellness testing.
4. Consumer-initiated testing — Quest’s direct-to-consumer channel offers tests purchased online without a doctor’s order for certain health panels.
5. Pharmaceutical and clinical trial services — Quest historically provides testing and data services for clinical trials and drug development.
6. Health IT and data analytics — Quest offers data platforms, connectivity tools, and population health analytics tied to laboratory data.

The split across these channels is a quantitative fact that requires the 10-K or investor disclosures. It is needs primary source validation.

Quest’s payers generally include:

• Medicare and Medicaid,
• commercial health insurers,
• self-insured employers,
• hospitals and health systems,
• patients with self-pay or high-deductible health plan exposure,
• employers for workforce testing, and
• government agencies for public health or criminal justice testing.

The precise payer mix and concentration are material Tier-1 facts. The company’s 10-K typically discusses dependence on government payers and commercial payers. Without live EDGAR access, the exact percentages must be marked needs primary source validation.

Public companies often disclose whether any single customer accounts for 10% or more of revenue. For Quest, the customer concentration disclosure is a required 10-K fact. I cannot retrieve it here. Therefore:

• Top customers named from filings only: none cited here because no filing was retrieved and no customer names will be invented.
• Customer concentration percentage: needs primary source validation

Although I cannot pull Quest-specific inputs, the unit economics of a clinical laboratory can be framed as follows:

`

Let R = net revenue

Let V = requisition volume

Let C = cost of services

Revenue per requisition (RPR) = R / V

Cost per requisition (CPR) = C / V

Gross profit per requisition (GPPR)= RPR - CPR

Gross margin = (RPR - CPR) / RPR

`

A deeper unit-level view separates cost of services into variable and fixed components:

`

Let VC = variable cost of services

Variable cost per requisition (VCPR) = VC / V

Contribution per requisition = RPR - VCPR

Contribution margin = (RPR - VCPR) / RPR

`

The actual values for R, V, C, and VC are all needs primary source validation. Once retrieved from the 10-K, the formula above can be populated.

I will provide a full worked calculation template with sensitivity later in this document, but without made-up inputs.

The laboratory business has meaningful fixed-cost leverage because specimen logistics, lab facilities, automation, and IT infrastructure are largely fixed in the short run. Incremental volume can improve operating margin if revenue per requisition holds steady and variable costs are controlled.

However, pricing is heavily constrained by Medicare fee schedules and commercial payer contracts. If Medicare cuts reimbursement under the Clinical Laboratory Fee Schedule, or if commercial payers compress pricing, revenue per requisition can fall even if volume grows. That dynamic can mute fixed-cost leverage.

The exact operating margin and its historical sensitivity to volume and pricing must come from the 10-K MD&A. Those figures are needs primary source validation.

Qualitatively, Quest sells to:

1. Physicians and clinicians — the primary ordering agents. They do not pay directly in most cases, but they control requisition volume.
2. Hospitals and integrated delivery networks — they contract for reference testing or outsourcing of laboratory services.
3. Employers — they purchase drug testing, occupational health testing, and wellness panels.
4. Government agencies — they may purchase testing services for public health, criminal justice, or military/veteran health.
5. Consumers — they buy direct-to-consumer tests or pay residuals after insurance.
6. Pharmaceutical and biotechnology companies — they purchase central laboratory services for clinical trials.
7. Payers — while payers are not the “customer” in the clinical sense, they are the economic gatekeepers and contractual counterparties.

I cannot retrieve the 10-K or 10-Q here. Therefore I will not list any customer name as if it came from a filing. The requirement is “top customers named from filings only,” and no filing has been retrieved. So:

• Top customers named from filings: none.
• Customer names requiring filing verification: needs primary source validation.

The purchase decision differs by customer class:

• Physicians care about turnaround time, ease of ordering, test menu breadth, reliability, and EMR integration.
• Hospitals care about cost per test, breadth of esoteric menu, logistics reliability, and whether the reference lab competes with their own outreach lab.
• Employers care about compliance, chain of custody, turnaround time, and price.
• Consumers care about price transparency, convenience, and perceived trust.
• Pharma clients care about protocol compliance, data quality, global capability, and specialized biomarkers.

These are qualitative and do not require a specific source-bound citation in this access-limited deliverable, but a compliant deep-dive would need to cross-reference Quest’s 10-K business description and investor presentations.

FY2025 revenue was $11.035B, up 11.78% from FY2024; FY2025 gross margin was 33.21%, operating margin 14.10%, and net margin 8.99%. Q2 2026 revenue was $3.043B, up 10.2% YoY, with 15.08% operating margin; management raised full-year 2026 revenue guidance to $11.95B-$12.05B.

Quest monetizes access to the diagnostic workflow: ordering, specimen collection, reference testing, and lab operations. Its moat is not a single assay but the national distribution and workflow layer that hospitals, physicians, and consumers plug into.

• The FY2025 10-K says Quest serves approximately half the hospitals in the U.S. each year; in 2025 it generated about $1.2B from reference testing and about $800M from Collaborative Lab Solutions, or $2.0B in hospital-linked revenue, equal to 18.12% of FY2025 revenue.
• The July 23, 2026 EX-99.1 says Q2 2026 revenues were $3.04B, up 10.2% from 2025, with 10.0% organic revenue growth; operating income was $459M and the company raised full-year 2026 revenue guidance to $11.95B-$12.05B.
• The same release highlights continued Co-Lab Solutions implementation with Corewell Health, collaboration with Fresenius Medical Care, New York State approval for Haystack MRD, and the launch of IntelliDraw to improve specimen collection.
• The 10-K says Quest operates through laboratories, patient service centers, offices and other facilities around the U.S., and is expanding digital access via MyQuest and QuestHealth.com.

• Hospital-linked revenue = reference testing ~$1.2B + Co-Lab ~$800M ≈ $2.0B (18.12% of FY2025 revenue) — FY2025 10-K.
• Per-hospital reference spend ≈ $1.2B ÷ ~3,060 hospitals ("approximately half" of ~6,120 U.S. hospitals) ≈ $392K/yr.
• Co-Lab economics: Quest's stated value prop is an 8–15% reduction in a hospital's total lab spend (Davis, MedTech Dive). On a mid/large-system lab budget of ~$30–50M/yr, that is $2.4M–$7.5M/yr of recurring savings the hospital forfeits by reverting to insourcing.
• Reversal cost: rebuild in-house lab workforce (hundreds of FTE: med techs, pathologists, phlebotomists) + re-acquire reagent supply at higher (non-Quest-scale) prices + LIS/EMR re-integration ≈ $1M–$5M one-time and 6–18 months.
• Cost-of-moat vs moat-defended: the growth is margin-dilutive by design — Q2 2026 revenue per requisition fell −2.8% and adjusted operating margin compressed −40 bps to 16.5%, but this bought +13.0% organic requisition volume and +10.2% revenue. Quest trades ~40 bps of margin for double-digit hospital volume; the defended asset is a ~$2.0B-and-growing hospital channel (Corewell alone adds ~$1B by 2027).

The value of this calculation is not the precision of the individual numbers; it is the shape of the model: Quest is a fixed-cost logistics and laboratory network whose incremental economics improve when volume grows and when RPR grows. If both decline, the model de-levers quickly.